For which adults with HR-positive, HER2-negative breast cancer is Trodelvy (sacituzumab govitecan) indicated as monotherapy?

Trodelvy (sacituzumab govitecan) monotherapy is indicated for adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the advanced setting.